2017
Cognition and the course of prodromal Parkinson's disease
Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition and the course of prodromal Parkinson's disease. Movement Disorders 2017, 32: 1640-1645. PMID: 29063713, PMCID: PMC5722226, DOI: 10.1002/mds.27189.Peer-Reviewed Original ResearchConceptsSpeed/attentionCognitive declineProdromal participantsBaseline neuropsychological test performanceExecutive function/Role of cognitionNeuropsychological test performanceFuture cognitive declineBaseline cognitive scoresCognitive domainsGlobal cognitionBaseline cognitionCognitive scoresCognitionTest performanceFuture declinePD-convertersDopamine systemHyposmic individualsProdromal PDLongitudinal changesFunction/ParticipantsDopamine transporter bindingIndividuals
2013
Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial
Hoffman RE, Wu K, Pittman B, Cahill JD, Hawkins KA, Fernandez T, Hannestad J. Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial. Biological Psychiatry 2013, 73: 1008-1014. PMID: 23485015, PMCID: PMC3641174, DOI: 10.1016/j.biopsych.2013.01.016.Peer-Reviewed Original Research
2012
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms
2010
Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis
Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis. JAMA Psychiatry 2010, 67: 578-588. PMID: 20530007, PMCID: PMC3332118, DOI: 10.1001/archgenpsychiatry.2010.66.Peer-Reviewed Original ResearchConceptsFamily historyCHR individualsNeuropsychological functioningCHR syndromeNorth American Prodrome Longitudinal StudyClinical high-risk individualsHigh-risk groupFirst-episode schizophreniaBaseline neuropsychological evaluationHigh-risk individualsSecond-degree relativesHigh-risk statusLongitudinal studyGlobal neuropsychological functioningWorse verbal memoryPrediction of psychosisCHR assessmentSyndrome criteriaProspective evaluationClinical criteriaModerate severityNeurocognitive composite scorePsychosis onsetNormal controlsSubsequent psychosis
2008
Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research 2008, 105: 1-9. PMID: 18774696, DOI: 10.1016/j.schres.2008.07.008.Peer-Reviewed Original ResearchConceptsNeuropsychological courseDouble-blind treatment studyNeuropsychological StatusPlacebo-assigned subjectsPutative prodromal stateDouble-blind trialFrank psychotic episodeEarly convertersOlanzapine treatmentNeuropsychological deficienciesFrank psychosisMedication studiesFirst episodePsychotic episodeProdromal stateHigh riskBlind trialNeuropsychological declineTreatment studiesPsychotic conditionsPsychosisLate convertersOlanzapineProdromeInitial assessment
2006
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal Of Psychiatry 2006, 163: 790-799. PMID: 16648318, DOI: 10.1176/ajp.2006.163.5.790.Peer-Reviewed Original ResearchConceptsOlanzapine patientsPlacebo patientsProdromal symptomsPsychosis ratesDouble-blind treatment periodEfficacy of olanzapineFurther treatment researchOlanzapine Versus PlaceboOlanzapine-treated patientsDouble-blind trialPhase of illnessPositive prodromal symptomsInduced Weight GainHazard of conversionSignificant differencesNorth American clinicsSignificant treatment differencesOlanzapine groupVersus PlaceboPlacebo groupSymptom scoresEfficacy measuresWeek 8Treatment periodPatients
2003
A Randomized Clinical Trial of a Manual-Guided Risk Reduction Intervention for HIV-Positive Injection Drug Users
Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A Randomized Clinical Trial of a Manual-Guided Risk Reduction Intervention for HIV-Positive Injection Drug Users. Health Psychology 2003, 22: 223-228. PMID: 12683743, DOI: 10.1037/0278-6133.22.2.223.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug usersHIV-positive injection drug usersHIV-seropositive injection drug usersHIV harm reduction programsRisk behaviorsHealth promotion behaviorsRisk reduction interventionsHarm reduction programsHigh-risk behaviorsAddiction severity scoresNational AIDS Demonstration Research projectAntiretroviral medicationsMethadone maintenanceSeverity scoreClinical trialsTreatment phasePromotion behaviorsReduction interventionsTreatment entryIllicit opiatesHarm reductionDemonstration research projectsPatientsReduction programs
1997
Normal neurocognitive performance after extended practice in patients with schizophrenia
Wexler B, Hawkins K, Rounsaville B, Anderson M, Sernyak M, Green M. Normal neurocognitive performance after extended practice in patients with schizophrenia. Schizophrenia Research 1997, 26: 173-180. PMID: 9323348, DOI: 10.1016/s0920-9964(97)00053-4.Peer-Reviewed Original ResearchConceptsWeeks of practiceSpecific neurocognitive tasksNormal neurocognitive performancePerformance of patientsImplicit learningMemory taskNeurocognitive tasksNeurocognitive performanceExtended practiceSame taskMotor tasksNeurocognitive improvementDifficulty levelOngoing instructionPerformance declineBase payTaskSupranormal performanceSchizophreniaHealthy controlsMemoryLearningInstructionTrainingPerformance